BBIO vs BHVN Stock Comparison
BBIO currently leads BHVN in this stock comparison, with AIQ scores of 64 vs 47. The clearest difference is quality, while BHVN has the stronger momentum profile.
What is the main difference between BBIO and BHVN?
BBIO leads the current stock comparison as BridgeBio Pharma, Inc., with the clearest separation coming from quality and the broader AIQ evidence mix.
AlgovestIQ AIQ Comparison
BridgeBio Pharma, Inc. vs Biohaven Ltd.
BBIO leads
BBIO leads by 17 AIQ points, primarily on Quality and Risk Resilience, and the lead has widened from 14 points over 30 sessions. Wall Street currently favors BHVN on target upside.
Competitive: 3 of 5 evidence groups support BBIO, its lead is widening, and its current signal state is conflicted.
BridgeBio Pharma, Inc.
Biohaven Ltd.
The Algovestiq AIQ Score currently favors BBIO over BHVN, 64 versus 47 as of Nov 15, 2026. BBIO's advantage is driven primarily by stronger quality and risk resilience, while BHVN holds the stronger momentum profile. BBIO also shows the stronger technical structure relative to its 50-day moving average, though analyst target upside currently favors BHVN. 3 of 5 covered evidence groups favor BBIO today, and the comparison is rated Competitive on stability: the leader is throwing conflicting signals. BBIO lead: Strengthening — the AIQ differential moved from 14 to 17 points over 30 sessions.
Compare BridgeBio Pharma, Inc. and Biohaven Ltd. across the Algovestiq AIQ Score, valuation, quality, momentum, risk, technicals and analyst expectations.
Performance over time
Price return from daily closes; distributions are not included.
Price return comparison
Growth of $10,000, price only
Split-adjusted closes only. Distributions are excluded, which understates the return of any fund or stock that pays them.
Compare BBIO and BHVN against another ticker
Open a multi-ticker workspace without changing this focused pair page.
AIQ Factor Divergence
Where the two separate, on the four dimensions behind the AIQ Score. Bars read outward from a shared zero: further from the centre is a wider gap.
- Quality66 vs 16BBIO +50
- Risk Resilience62 vs 35BBIO +27
- Momentum69 vs 78BHVN +9
3 of 5 evidence groups favor BBIO. BBIO’s edge is concentrated in quality and risk resilience; BHVN keeps a meaningful momentum edge.
What changed since the last close
Latest scored session 2026-11-13, compared against the prior scored session 2026-11-12.
Largest factor move: Quality +1
No signal started or stopped since the prior session; its 5 active signals are unchanged.
Largest factor move: Momentum +1
New signals
- ADX Trend Weakening — neutral, trend, medium horizon
BBIO's lead was unchanged in the latest session.
Deeper signal detail for each name lives on its own signals page — BBIO and BHVN both carry a full feed there.
The central trade-off
BBIO (BridgeBio Pharma, Inc.): the stronger current systematic profile, led by quality and risk resilience.
BHVN (Biohaven Ltd.): the counter-case, on momentum, analyst expectations — but at materially higher volatility, 114.5% against 39.1%.
The AIQ Score and Wall Street therefore point in different directions on this pair.
Which one fits your objective
The same two names rank differently depending on what you are optimizing for. All six reads are shown at once — none of them is hidden behind a toggle.
Balanced
BBIOBBIO on the overall AIQ Score, which weights Quality and Value most heavily.
Growth
BBIOBBIO on combined revenue and EPS growth.
Value
EvenThe two are level on Value.
Momentum
BHVNBHVN on the Momentum factor, by 9 points.
Lower downside
BBIOBBIO on Risk Resilience, by 27 points.
Analyst upside
BHVNBHVN on implied upside to the consensus price target.
AIQ vs Wall Street
The model and the Street disagree here: AIQ favors BBIO, analyst targets favor BHVN. That disagreement is the most useful thing on this page.
| Measure | BBIO | BHVN | Note |
|---|---|---|---|
| Implied upside to target | +42% | +113.5% | BHVN has more room |
| Target dispersion | +62.1% | +98.3% | Lower is tighter analyst agreement |
| Consensus | Buy | Buy | Context, not a primary driver |
| Analysts covering | 22 | 17 | Higher coverage generally improves confidence |
The two are measuring different things. The AIQ Score reads current fundamentals, valuation, trend and risk; analyst targets price forward expectations. A divergence of this kind is either a contrarian opportunity or a sign the model is missing something already priced in — it is worth resolving before acting on either.
Analyst targets are expectations, not predictions. Dispersion matters as much as the midpoint.
AIQ Agreement Matrix
3 of 5 covered evidence groups favor BBIO. A wide gap backed by one group is a weaker case than a narrow gap backed by five.
| Evidence group | Favors | Reading |
|---|---|---|
| AIQ Score | BBIO | 64 vs 47 |
| Fundamentals | Even | EPS growth 46.2% vs 5.5%; TTM ROE 3.4% vs 131.6% |
| Valuation | Not covered | Not covered |
| Technicals | BBIO | Price vs 50-day 11.9% vs 2.2%; vs 200-day 7.7% vs 12.1% |
| Risk Resilience | BBIO | Risk Resilience 62 vs 35 |
| Analyst expectations | BHVN | Target upside 42% vs 113.5% |
✓ agrees with the overall verdict · ✕ points the other way. Groups marked “not covered” lack data on one or both of BBIO and BHVN and are excluded from the count.
AIQ Decision Stability
The two are close enough that your objective, not the score, should decide.
- The AIQ gap is wide at 17 points. (supports the conclusion holding)
- The leader's advantage has been widening. (supports the conclusion holding)
- The lead has been steady session to session. (supports the conclusion holding)
- The leader is throwing conflicting signals. (argues the conclusion is provisional)
- Analyst targets on the leader are widely dispersed. (argues the conclusion is provisional)
Stability combines the score gap, how broadly the evidence agrees, how steady the lead has been across daily snapshots, the current signal state on both names, and analyst dispersion on BBIO.
How the comparison changed
120 daily snapshots · May 27 – Nov 13BBIO lead: Strengthening — the AIQ differential moved from 14 to 17 points over 30 sessions.
- Today
- BBIO +17
- 64 vs 47
- 7 sessions ago
- BBIO +14
- 62 vs 48
- 30 sessions ago
- BBIO +14
- 50 vs 36
- 90 sessions ago
- BBIO +14
- 59 vs 45
The lead has not changed hands in this window.
AIQ Signal Divergence
Only the signals that bear on the head-to-head. A conflicted name is carrying bullish and bearish rules at the same time — the technical evidence is not pointing one way.
2 bullish / 2 bearish / 1 neutral, conflicted
Only BBIO
- Death Cross Active — bearish, trend, long horizon (3.88%)
- ADX Trend Strengthening — neutral, trend, medium horizon
- TRIX Bullish Signal — bullish, momentum, short horizon
3 bullish / 3 bearish / 2 neutral, conflicted
Only BHVN
- Golden Cross Active — bullish, trend, long horizon (9.68%)
- ADX Trend Weakening — neutral, trend, medium horizon
- ATR Expansion - Breakout Mode — neutral, volatility, short horizon (7.52%)
- Beta Spike Warning — bearish, risk_regime, long horizon
- MACD Histogram Expanding Bearish — bearish, momentum, short horizon
- Uptrend Structure Active — bullish, trend, long horizon
Both carry 2 more signals that do not separate them: EMA Ribbon Expansion Bullish, Low Volume Rally Warning.
BBIO leads the comparison while carrying a conflicted signal state, which is one reason the stability rating is not higher.
Price vs model alignment
Whether the latest session's price move confirms what the model did over the same session, or contradicts it.
Price and the AIQ Score both moved up over the latest session (price +0.17%, AIQ +1 points).
Price is down while the AIQ Score moved up 1 points over the same session — price and model disagree (price -1.78%, AIQ +1 points).
What would flip this result
A state, not a forecast. These are the specific, observable changes that would reverse the verdict — not a price prediction.
- 1BHVN closes the Quality gap — currently 50 points behind, the largest single contributor to BBIO's edge.
- 2BHVN's Beta Spike Warning resolves — a bearish risk_regime rule currently active against it.
- 3BBIO's conflicting signal state resolves bearish — it currently carries 2 bullish and 2 bearish rules at once.
- 4A market regime shift would change the factor readings behind both scores; a rotation toward or away from quality, value or momentum could move the result.
The full evidence
Every number behind the verdict. The leader is called above each group so you are not left to solve it from the table.
Fundamentals
Split| Metric | BBIO | BHVN |
|---|---|---|
| Revenue growth (YoY) | 44.9% | 0% |
| EPS growth (YoY) | 46.2% | 5.5% |
| Gross margin | 93.5% | 0% |
| Operating margin | -43.4% | 0% |
| Return on equity (TTM) | 3.4% | 131.6% |
| Debt to equity | -1.5 | -3.06 |
Performance
BHVN leads 4 of 6 windows| Metric | BBIO | BHVN |
|---|---|---|
| 1 week (5 sessions) | 5.4% | -4.6% |
| 1 month (20 sessions) | 17.9% | 28.2% |
| 3 months (63 sessions) | -2% | -4.4% |
| 6 months (126 sessions) | 18.4% | 57.8% |
| Year to date | 2.4% | 22.4% |
| 1 year (252 sessions) | 18.2% | 73.8% |
Technicals
BBIO has the stronger structure| Metric | BBIO | BHVN |
|---|---|---|
| RSI (14) | 65 | 47.8 |
| ADX (14) | 38.9 | 24.5 |
| Price vs 50-day | 11.9% | 2.2% |
| Price vs 200-day | 7.7% | 12.1% |
| Volatility (1M, annualized) | 39.1% | 114.5% |
Risk
BBIO is the more resilient| Metric | BBIO | BHVN |
|---|---|---|
| Beta | 0.95 | 1.28 |
| Sharpe ratio | 0.55 | 1 |
| Sortino ratio | 0.84 | 1.74 |
| Max drawdown | -29.8% | -41.2% |
| Current drawdown | -13.2% | -18.5% |
| Annualized volatility | 44.1% | 83% |
| Value at risk (95%) | -4% | -6.7% |
Straight answers
Each answer is regenerated from the current snapshot, not written once and left to age.
Which is better, BBIO or BHVN?
On the Algovestiq AIQ Score, BBIO is the stronger of the two as of Nov 15, 2026, scoring 64 against BHVN's 47. The edge comes from quality and risk resilience. BHVN is not without a case — it holds the better momentum profile, which matters more if that is the objective you are optimizing for. This is a systematic score, not a recommendation: it ranks the two on the same evidence, it does not know your holding period or tax position.
Is BBIO or BHVN the better buy right now?
BBIO carries the stronger systematic profile as of Nov 15, 2026, and the comparison is rated Competitive — 3 of 5 covered evidence groups agree. A Competitive rating means the two are close enough that your objective, not the score, should decide.
Why does the AIQ Score favor BBIO over BHVN?
The composite weights Quality, Value, Momentum and Risk Resilience. BBIO leads Quality by 50 points; BBIO leads Risk Resilience by 27 points; BHVN leads Momentum by 9 points. Where the two split, the factor with the larger weight carries the result.
Which has more analyst upside, BBIO or BHVN?
Analyst price targets imply +42% upside for BBIO and +113.5% for BHVN, so the Street currently favors BHVN. That points the opposite way to the AIQ Score, which favors BBIO. The two are measuring different things: the model reads current fundamentals, valuation, trend and risk; the Street is pricing forward expectations. A divergence of this kind is either a contrarian opportunity or a sign the model is missing something the analysts have already priced — it is the single most useful row on this page to investigate. Analyst targets are expectations, not predictions, and dispersion matters as much as the midpoint.
Which is better value, BBIO or BHVN?
Neither name separates on the peer-relative Value factor. The two are level on Value. The Value factor reads valuation relative to sector peers and to the company's own fundamental quality, so it is not the same as simply having the lower multiple.
Which has stronger growth, BBIO or BHVN?
BBIO on combined revenue and EPS growth. Growth here is measured on reported revenue and earnings, not on forward estimates — it describes what the businesses have delivered, not what the Street expects next.
Which has stronger momentum, BBIO or BHVN?
BHVN on the Momentum factor, by 9 points. Momentum is one of the four weighted factors in the AIQ composite. It has documented persistence over three- to twelve-month horizons, which makes it a timing input rather than a reason to hold something indefinitely.
Which is riskier, BBIO or BHVN?
BBIO is the more resilient of the two, so the other name carries the higher downside risk. BBIO on Risk Resilience, by 27 points. Risk Resilience is a weighted factor in the composite; position sizing usually responds to it more usefully than the buy/avoid decision does.
Is BBIO more profitable than BHVN?
BHVN leads on the comparable margin measures — gross margin 93.5% vs 0%; operating margin -43.4% vs 0%; ttm roe 3.4% vs 131.6%.
Is BBIO's lead over BHVN getting stronger or weaker?
BBIO lead: Strengthening — the AIQ differential moved from 14 to 17 points over 30 sessions. This is measured from 120 daily comparison snapshots between 2026-05-27 and 2026-11-13. The lead has not changed hands in that window.
What would change the BBIO vs BHVN verdict?
The result is a state, not a forecast, so it changes when the underlying evidence changes. Concretely: BHVN closes the Quality gap — currently 50 points behind, the largest single contributor to BBIO's edge; BHVN's Beta Spike Warning resolves — a bearish risk_regime rule currently active against it; BBIO's conflicting signal state resolves bearish — it currently carries 2 bullish and 2 bearish rules at once; a market regime shift would change the factor readings behind both scores; a rotation toward or away from quality, value or momentum could move the result.
What do the current signals say about BBIO and BHVN?
BBIO: 2 bullish / 2 bearish / 1 neutral, conflicted. BHVN: 3 bullish / 3 bearish / 2 neutral, conflicted. A conflicted state means bullish and bearish rules are active on the same name at once — the technical evidence is not pointing one way, and a decision taken on it carries more timing risk. The most decision-relevant rule on BBIO is Death Cross Active (bearish, long horizon). On BHVN it is Golden Cross Active (bullish, long horizon).
Compare BBIO and BHVN with others
Continue your research
This page answers which of the two. These answer the questions on either side of it.
How this comparison is scored
The Algovestiq AIQ Score composites four factors — Quality, Value, Momentum and Risk, each carrying a fixed weight. Sentiment is reported separately as SentimentPulse and is not folded into the composite. Scores refresh every trading day, and this page regenerates from the latest snapshot rather than being written once.
The verdict names a leader, states how broadly six independent evidence groups agree, and rates how durable that conclusion is given the score gap, its recent trajectory and the current signal state on both names.
How to use side-by-side comparison →This comparison is informational and educational, not investment advice. AIQ scores update daily; re-check after earnings, guidance or macro data that materially changes either name’s factor profile.